LineBacker04
$CAPR
Part-2
1. CAPR analysis based on data
So, following these principles, I did a deep dive into all previous FDA evaluations where a drug was controversially voted against followed by an amendment and an extension, and the data shows a clear trend.
a) In April 25, 2016 an FDA panel voted 3–7 against Sarepta's Exondys 51 which, following an extension was approved in September 2016.
b) In March 2022, Amylyx's Relyvrio was voted down 4-6 by an AdCom panel and subsequently approved after an extension
c) Biogen's Aduhelm also went through the same trajectory - voted 0-10 against and approved after a 6 month extension
In all cases where the FDA accepted an extension (meaning there's something meaningful beyond what was discussed in the AdCom) the applications were APPROVED with one caveat - the only thing that tripped up an application was major safety concerns.
I ran the analysis on a much larger data set - but the ones closest to our application were really the three discussed above.
1
109
